Dr. Colin Murdoch

Colin Murdoch

Dr Murdoch joined the Vascular Medicine Section within Aston Medical School in October 2013 and was awarded a Marie Skłodowska-Curie International Incoming Fellowship to disseminate cardiovascular in vivo techniques and Redox vascular pathophysiology to Aston University and the wider EU community.  

Previously he spent 3-years in the US working with Richard Cohen and Reiko Matsui at the Whitaker Cardiovascular Unit, School of Medicine Boston University investigating the role of redox signalling in neovascularisation.

Dr Murdoch’s post-doctoral research and Ph.D took place in the BHF Centre of Excellence at King’s College London under the supervision of the talented Prof Ajay Shah.  Where he investigated oxidative stress signalling in left ventricular hypertrophy, diastolic dysfunction and hypertension.  

Before he undertook a Ph.D Dr Murdoch spent five-years working in industry for Pharmagene (now Asterand) as a Scientist in the Functional Pharmacology department where among other roles he was an integral member of a team which developed a potential migraine treatment which discovered a novel therapeutic mechanism and drug in Phase Two clinical trials. His initial contact with Pharmagene was through an Industrial Placement as part of an undergraduate course Pharmacology with Industrial Experience at the University of Edinburgh.  

  • Position:  Marie Skłodowska-Curie International Incoming Fellow
  • Telephone: 0121 204 3920
  • Email:  c.murdoch@aston.ac.uk

2004 -2009 - British Heart Foundation Ph.D student.  King’s College London, UK. Research Project:  Influence of endothelial redox state on cardiac remodelling in response to chronic pressure overload.

1996 – 2000 - Undergraduate Pharmacology with Honors and Industrial Placement University of Edinburgh, UK.

2014 - Marie Curie International Fellow

2011- 2013 - Post-Doctoral Research Scholar
Cohen Laboratory, Vascular Biology Unit. Boston

School of Medicine. Boston University, MA.

2009 -2011 - Post-Doctoral Fellow.  Cardiovascular Division, BHF Centre of Excellence, King’s College London, UK.

2004 -2009 - British Heart Foundation Ph.D student.  King’s College London, UK. Research Project:  Influence of endothelial redox state on cardiac remodeling in response to chronic pressure overload.

2000 -2004 - Scientist, Asterand PLC.  Royston UK.

MSc – Student Placements

I am interested in how redox signaling affects cardiovascular pathophysiology.  In particular my research has concentrated on signaling in the endothelial and inflammatory cell and the implication on cardiovascular function in vivo.  I am currently investigating a number of targets in pre-eclampsia using a wide range of clinical samples, murine models and in vitro studies.  One aspect is to investigate during pre-eclampsia whether signaling is affected by the S- glutathionylation, a post-translation modification which occurs during oxidative stress.  

My previous research in Boston was to identify how angiogenesis can be regulated by S- glutathionylation.  In Kings College London I investigated the cell specific role of isoforms of the NADPH oxidase enzymes, Nox2 and Nox4 in the endothelium on left ventricular hypertrophy and hypertension. I successfully modeled a human disease in a mouse, measured cardiovascular parameters and subsequently conducted biochemical and molecular assays in order to identify novel molecular mechanisms.  

I have spent time working in industry where I helped find novel targets for disease and tested possible drug candidates.  

EU- Marie Curie International Fellowship

MSc Students

  • Ms Athina Georgiadou
  • Mr Suni Sahota


Undergraduate Placement Students

  • Ms Sophie Broadway-Stringer
  • Ms Milda Bartkeviciute


  • American Heart Association
  • EU Heart Failure Association
  • Society for Free Radical Biology
  • Reviewer for  Journal of Cellular and Molecular Medicine  Antioxidant Redox Signalling


  1. Murdoch CE, Chaubey S, Zeng L, Yu B, Ivetic A, Walker SJ, Vanhoutte D, Heymans S, Grieve DJ, Cave AC, Brewer AC, Zhang M, Shah AM.  Endothelial NADPH oxidase-2 promotes interstitial cardiac fibrosis and diastolic dysfunction through pro-inflammatory effects and endothelial-mesenchymal transition. J Am Coll Cardiol. 2014 Mar 14. pii: S0735-1097(14). (Accompanied by editorial).
  2. Murdoch CE, Shuler M, Haeussler DJ, Kikuchi R, Bearelly P, Han J, Watanabe Y, Fuster JJ, Walsh K, Ho YS, Bachschmid MM, Cohen RA, Matsui R.  Glutaredoxin-1 Up-regulation Induces Soluble Vascular Endothelial Growth Factor Receptor 1, Attenuating Post-ischemia Limb Revascularization.  J Biol Chem. 2014 Mar 21;289(12):8633-44
  3. Drozdov, A Didangelos, X Yin, A Zampetaki, M Abonnenc, CE Murdoch, M Zhang, C Ouzounis, M Mayr, S Tsoka, Ajay M Shah. Gene network and proteomic analyses of cardiac responses to pathological and physiological stress .  Circ Cardiovasc Genet. 2013.  Nov 8.
  4. Murdoch CE, Alom-Ruiz SP, Wang M, Walker S, Yu B, Brewer AC, Shah AM. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol. 2011 Jun;106(4):527-38. (Accompanied by editorial).
  5. Murdoch CE, Ray R, Wang M, Zhang M, Alom-Ruiz S, Ouattara A, Cave AC, Walker SJ,Grieve DJ, Charles R, Eaton P, Brewer AC, Shah AM. Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol.  2011. Jun;31(6):1368-76. (Accompanied by editorial). 
  6. Webb IG, Nishino Y, Clark JE, Murdoch C, Walker SJ, Makowski MR, Botnar RM, Redwood SR, Shah AM, Marber MS. Constitutive glycogen synthase kinase-3(α)/(β) activity protects against chronic(β)-adrenergic remodelling of the heart. Cardiovasc Res. 2010;Mar ; 87(3):494-503.
  7. Humphries J, Gossage JA, Modarai B, Burnand KG, Sisson TH, Murdoch C, Smith A. Monocyte urokinase-type plasminogen activator up-regulation reduces thrombus size in a model of venous thrombosis. J Vasc Surg. 2009; Nov;50(5):1127-34.
  8. Kis A, Murdoch C, Zhang M, Siva A, Rodriguez-Cuenca S, Carobbio S, Lukasik A, Blount M,O'Rahilly S, Gray SL, Shah AM, Vidal-Puig A. Defective peroxisomal proliferators activatedreceptor gamma activity due to dominant-negative mutation synergizes with hypertension toaccelerate cardiac fibrosis in mice. Eur J Heart Fail. 2009; Jun;11(6):533-41.
  9. Davis RJ, Murdoch CE, Ali M, Purbrick S, Ravid R, Baxter GS, Tilford N, Sheldrick RL, Clark KL, Coleman RA. EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br J Pharmacol. 2004;141:580-585.


  1. Dworakowski R, Murdoch CE, Shah AM. NADPH oxidases as pivotal sources of ROS in cardiac disease. Nova Acta Leopoldina NF 2008;351:47-53 
  2. Sirker A, Zhang M, Murdoch C, Shah AM.  Involvement of NADPH oxidases in cardiac remodelling and heart failure. Am J Nephrol. 2007;27:649-660
  3. Murdoch CE, Zhang M, Cave AC, Shah AM. NADPH oxidase-dependent redox signalling in cardiac hypertrophy, remodelling and failure. Cardiovasc Res.  2006;71:208-215.
  4. Murdoch CE, Grieve DJ, Cave AC, Looi YH, Shah AM. NADPH oxidase and heart failure. Curr Opinion Pharmacol. 2006;2:148-153 
  • 2012:  Travel Award for Abstract submitted to Society for Free Radical Biology and Medicine 19th Annual   Meeting, San Diego.
  • 2008:  Blue Riband presentation prize at National Physiology society meeting, UK.
  • 2007:  King’s travel award 
  • 2005:  1st Place poster award at King’s College London Graduate Studies Day.